Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Investigation

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).

Since late 2016, the Company has been the subject of investigations by numerous legal and regulatory authorities and significant litigation relating to its use of a myriad of unethical and possibly illegal sales and promotion campaigns by its salespeople in connection with its flagship drug, Soliris.

The actions of the Company, as directed by its executives, have exposed it to significant financial losses, an exodus of high-level executives, investigations by the U.S. Securities and Exchange Commission, the U.S. Department of Justice, the U.S. Attorney’s Office for the District of Massachusetts, the U.S. Department of Health and Human Services and Brazilian law enforcement officials.  Further, the Company has been sued in an ongoing securities class action lawsuit for failing to disclose material information and has also received a formal demand for inspection of its books and records made by a shareholder.  Recently, a shareholder derivative lawsuit was filed against the Company’s current and former executives.

KSF’s investigation is focusing on whether Alexion’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Alexion shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com).